Day: 2026年2月10日

TOKYO, Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - Ahead of the start of the 2026 FIA*1 Formula One World Championship (F1TM) season, Honda works partner Aston Martin Aramco Formula One™ Team (AMAF1), has unveiled the livery for its new F1 machine, the AMR26. Powered by the Honda F1 power unit, the RA626H, the AMR26 will take on the challenge of F1, the pinnacle of automobile racing.The AMR26 is the first F1 machine designed for the team by Adrian Newey, AMAF1 Managing Technical Partner and Team Principal, and it is being developed at the AMR Technology Campus, at AMAF1 headquarters in Silverstone, the U.K.Together with AMAF1, Honda will conduct pre-season testing in Bahrain for a total of six days, — February 11-13 and 18-20 — and make necessary adjustments before taking on the season-opening race at the Australian Grand Prix on Sunday, March 8, 2026.*1 Fédération Internationale de lʼAutomobileComments by Adrian Newey, Managing Technical Partner and Team Principal, Aston Martin Aramco Formula One™ Team“2026 is a rare moment in Formula One because, for the first time, the chassis and power unit regulations have changed together. With brand-new regulations, the best philosophy is never immediately obvious, and your understanding evolves as the car develops. With the AMR26 we’ve taken a holistic approach: it’s not about one standout component, but how the full package works together. The focus has been on strong fundamentals, development potential, and a car that Lance and Fernando can extract performance from consistently.”Comments by Koji Watanabe, President of Honda Racing Corporation (HRC)“Getting ready for the start of the 2026 F1 season where we will compete with a completely new chassis and power unit, Honda/HRC has been developing the RA626H, the new power unit which will power the AMR26, the new machine of our works partner, Aston Martin Aramco Formula One™ Team. As one united team with AMAF1, we are delighted to take this first step into a highly demanding, yet most exciting challenge in the world of motorsport.”Aston Martin Aramco Formula One™ Team drivers No.DriverAgeNationalityBest F1 result in 202514Fernando Alonso44Spain10th18Lance Stroll27Canada16th Fernando Alonso Lance Stroll ＜For reference＞2026 F1 race calendar RoundRace dateGrand Prix*LocationRace start timeLocal timeJapan timeRound 1March 8AustraliaMelbourne15:0013:00Round 2March 15ChinaShanghai15:0016:00Round 3March 29JapanSuzuka14:0014:00Round 4April 12BahrainSakhir18:0000:00 (Apr.13)Round 5April 19Saudi ArabiaJeddah20:0002:00 (Apr.20)Round 6May 3MiamiMiami16:0005:00 (May 4)Round 7May 24CanadaMontreal16:0005:00 (May 25)Round 8June 7MonacoMonaco15:0022:00Round 9June 14Barcelona-CatalunyaBarcelona15:0022:00Round 10June 28AustriaSpielberg15:0022:00Round 11July 5Great BritainSilverstone15:0023:00Round 12July 19BelgiumSpa-Francorchamps15:0022:00Round 13July 26HungaryBudapest15:0022:00Round 14August 23NetherlandsZandvoort15:0022:00Round 15September 6ItalyMonza15:0022:00Round 16September 13SpainMadrid15:0022:00Round 17September 26AzerbaijanBaku15:0020:00Round 18October 11SingaporeSingapore20:0021:00Round 19October 25United StatesAustin15:0005:00 (Oct. 26)Round 20November 1MexicoMexico City14:0005:00 (Nov. 2)Round 21November 8BrazilSão Paulo14:0002:00 (Nov. 9)Round 22November 21Las VegasLas Vegas20:0013:00 (Nov. 22)Round 23November 29QatarLusail19:0001:00 (Nov. 30)Round 24December 6Abu DhabiYas Island17:0022:00*Short names for each Grand Prix. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Japan, Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. (Honda) today announced that the company will make organizational and operational changes, effective April 1, 2026, in order to sustainably offer the joy and freedom of mobility all around the world through its mobility products and services.In 2020, with the aim of solidifying its existing business while preparing for future growth, Honda separated two key research and development functions — the development of production models and research on future technologies — enabling each group to focus on its roles. This initiative generated solid results including contribution to Honda business and the enhancement of technological competitiveness.With the global business environment surrounding Honda changing faster than expected, the company will further strengthen its ability to grasp market and technology trends more accurately and deliver the original technologies and new value of Honda to the market at the optimal timing. Toward this goal, Honda will make changes to the organizational structure of the Automobile Development Operations and the Automobile Operations.Moreover, the Motorcycle and Power Products Operations will also undergo some organizational changes to ensure future growth. Details of the organizational changes effective April 1, 20261) Consolidation of automobile R&D functions at Honda R&D Co., Ltd.The R&D functions of the Automobile Development Operations and the SDV Business Development Unit within the Automobile Operations will be transferred to Honda R&D Co., Ltd., the R&D subsidiary of Honda.Since 2020, the two key research and development functions — the development of production models and research on future technologies — have been operated separately so that each group can focus on its roles. However, in order to further enhance the strengths of its products, Honda will make organizational changes to build a structure where the entire process — from the selection of technology themes through product market launches — is viewed as one integrated flow to drive the entire process at speed, while flexibly responding to the changes in business environment. Through this change, Honda R&D will be further advanced as a R&D organization capable of continuing to create compelling products, through which Honda will further increase its competitiveness.2) Reorganization of Automobile Operations The Automobile Business Strategy Unit and Sales Unit will be reorganized into the Business Strategy Unit and Regional Business Unit, which will be newly created effective April 1, 2026. In addition, the business functions currently being served by the SDV Business Development Unit will be reorganized into the new Business Strategy Unit, and the SDV Business Development Unit will be disbanded.Through these organizational changes, for the earliest improvement of the profitability of its automobile business, Honda will 1) enhance its product planning and sales capabilities in light of market dynamics and customer needs, and 2) strengthen the competitiveness of its products from the mid- to long-term perspectives. 3) Reorganization of Motorcycle and Power Products Operations As the electrification strategy for motorcycle and power products business has transitioned into the execution stage, sales, business strategy and product development functions currently being served separately for electrification business and ICE (internal combustion engine) business will be integrated. Through the integrated management of electrification and ICE business, Honda will pursue optimal allocation of resources and continue initiatives toward carbon neutrality, while striving to ensure the continuous creation of increasingly competitive products. Through these organizational changes, Honda will further accelerate ongoing initiatives for its corporate transformation through electrification and new value creation, through which Honda will strive to establish a more distinctive presence as “a company society wants to exist” even in the era of electrification and intelligent technologies. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - KS Energy Co., Ltd. ("KS Energy"), a renewable energy business company and Hitachi, Ltd. (TSE:6501, “Hitachi”) agreed on February 6 to collaborate on the development and operation of an Extra-High Voltage Grid Battery Energy Storage System*1 within Kumamoto Prefecture, as well as the development and operation of power trading businesses. Hitachi will provide project development support for KS Energy's development of the project and jointly promote the development and operation of this battery energy storage system (tentative name)*2 . Additionally, KS Energy will also explore the introduction of a power trading support system planned for development by Hitachi.This initiative will support stable power supply in the Kyushu region and contribute to achieving carbon neutrality.*1 Extra-High Voltage Grid Battery Energy Storage System: Large-scale battery storage facilities directly connected to the power grid (such as transmission lines) with a capacity of 2,000 kW or more.*2 Power Trading Support System: A power trading support system for operators managing large-scale grid-connected storage batteries. It supports traders' daily operations comprehensively—from bid planning and market transactions to submitting plans to OCCTO—across both the supply-demand adjustment market and the wholesale electricity market. System development also incorporates collaboration with other companies, such as bid plan optimization services. This contributes to improved profitability through trading based on optimal bid plans and streamlines routine daily tasks like plan submission.BackgroundRenewable energy generation fluctuates due to weather changes and other factors, significantly impacting the power supply-demand balance. Particularly in the Kyushu region, where renewable energy adoption is advancing, output curtailment occurs frequently when generation exceeds demand. Securing balancing power to stabilize the power grid is an urgent priority. Furthermore, as the policy framework for promoting renewable energy shifts from the FIT (Feed-in Tariff) system to the FIP (Feed-in Premium) system, power generators are now required to develop their own electricity trading capabilities to formulate strategies for selling electricity in the power market. Against this backdrop, the importance of "aggregators" – entities that consolidate and control energy resources to adjust supply-demand balance – is growing. They are expected to contribute to the effective utilization and stable supply of renewable energy by engaging in both the electricity market and the power trading market.To address this situation, KS Energy, established in January 2024 with full investment from Higo Bank, Ltd. (part of the Kyushu Financial Group), has adopted a policy to contribute to stabilizing power supply as a regional energy company, aiming to make the entire Kyushu region a leading area for renewable energy circulation. Meanwhile, Hitachi has a long history in the power sector, providing a wide range of advanced solutions from energy storage systems to transmission and distribution infrastructure and grid protection devices.Through this collaborative effort, both companies will combine their respective strengths. By developing and operating energy storage facilities and engaging in power trading, they aim to achieve carbon neutrality in the Kyushu region.Initiative DetailsKS Energy and Hitachi have decided to jointly develop and operate battery energy storage system in the Kyushu region. This initiative contributes to stabilizing local power supply by charging and discharging in response to electricity demand-supply balance, thereby providing balancing power.1. Nation's First Extra-High Voltage Battery Energy Storage System project launched by a regional bank group This marks the first instance nationwide of a bank subsidiary's renewable energy business company undertaking a grid energy battery business in the extra-high voltage range. Through this initiative, we aim to contribute to stable power supply. Additionally, KS Energy is considering managing the power trading for the storage facility in-house. The plan involves handling the entire operational process: forecasting electricity market prices, creating power generation (charging/discharging) plans for the batteries, controlling the storage facility, and monetizing through market transactions. In the future, leveraging its operational expertise in storage facilities and collaborating with Higo Bank, KS Energy will enhance support for power generators and provide financing support to storage facility developers. This will enable the delivery of services extending beyond the financial sector, promote efficient electricity usage within local communities, and contribute to achieving regional carbon neutrality and decarbonization.2. Joint Promotion of Project Development from the Early Stage Leveraging Hitachi’s extensive experience in battery energy storage systems, Hitachi and KS Energy will jointly promote the development of energy storage facilities. The Hitachi Group will work together to promote project development through to operational launch. This includes cooperation from grid connection application discussions with transmission and distribution operators to applications and procedures with relevant ministries and agencies, provision of business feasibility evaluation information, supply of Hitachi Energy-manufactured PCS, and project management covering equipment design, procurement, and installation. Hitachi will sustainably support KS Energy's stable operations of the storage facility.3. Collaboration in Power Trading Business To stably utilize rapidly expanding renewable energy, the need for aggregation functions that balance electricity supply and demand is growing. KS Energy is considering introducing Hitachi's planned power trading support systemto achieve efficient energy resource utilization and aim for stable power supply. Under Hitachi's Lumada 3.0 initiative, the company is deploying "HMAX by Hitachi" (hereinafter HMAX), a next-generation AI solution suite that tackles the most complex challenges facing social infrastructure. This is achieved by combining vast data from both physical and digital assets with advanced AI enhanced by Hitachi's unique deep domain knowledge. In the electric power trading area as well, Hitachi will realize services that optimize the operation of storage battery assets and maximize market value, and aim to deploy them as HMAX.Future DevelopmentsKS Energy and Hitachi will collaborate to achieve both the mainstreaming of renewable energy as a primary power source and stable supply through the development of battery energy storage system and enhanced aggregation functions, working together toward realizing regional carbon neutrality.Overview of Grid-Connected Storage FacilityStorage Facility Name : (Provisional name) KSE Kumamoto Battery Energy Storage SystemStorage Facility Location (Planned) : Within Kumamoto PrefectureRated Output/Rated Capacity (Planned) : 50,000 kW / 112,880 kWhScheduled Start of Operation : January 2029 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and CAMBRIDGE, Mass., Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration (NMPA) of China.The Priority Review and Approval Procedure was implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened.If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration every two weeks in a hospital setting. The potential approval of SC-AI would expand the option for patients and care partners to receive LEQEMBI treatment at home. The injection time for each autoinjector (250 mg injection) is approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion and nurse monitoring, while streamlining the overall AD treatment care pathway.Eisai estimates that there were 17 million patients with MCI or mild dementia due to AD in China in 2024, which is expected to increase with the aging of the population. LEQEMBI was launched in China in June 2024 and has been delivered in the private market. Furthermore, LEQEMBI has been included in the newly introduced “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), which took effect in January 2026, under new Chinese government policies that support the development of and access to innovative medicines. Based on the Commercial Insurance Innovative Drug List, Commercial insurance companies will develop insurance products covering LEQEMBI.Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In China, Eisai will distribute the product and conduct information provision activities through specialized Medical Representatives.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com About LEQEMBI (generic name: lecanemab, Chinese brand name: 乐意保)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 7 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China. Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About ProtofibrilProtofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.For more information, visit https://www.eisai.com/news/2026/pdf/enews202608pdf.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com